Vasküler Behçet Hastalığı Tanısı Olan Hastalarımızın Klinik Özellikleri, Tedavi Protokolleri ve Relaps Oranları: Tek Merkez Deneyimi

Yıl 2021, , 323 - 326, 01.12.2021

Belkis Nihan Coskun , Burcu Yağız , Zeliha Çakan , Yavuz Pehlivan , Hüseyin Ediz Dalkılıç

https://doi.org/10.32708/uutfd.983701

Öz

Bu çalışmada, vasküler Behçet Hastalığı (BH) tanısı ile izlediğimiz hastaların klinik, demografik verilerinin değerlendirilmesi, relaps sıklığı ve kullanılan tedavilerle olan ilişkisinin irdelenmesi amaçlanmıştır. BH tanılı 512 hastanın dosyası geriye dönük incelenerek 68 vasküler tutulumlu Behçet hastası tespit edildi. Demografik özellikler, birinci vasküler olay ve varsa nüksü, tedavi protokolleri kaydedildi. Vasküler tutulum sıklığı %13,28’idi. Hastaların %85’i erkekti. En sık alt ekstremitelerde venöz tutulum görüldü (%77,9). İlk vasküler relaps, hastaların %29,4’inde, ikinci vasküler relaps ise %8,8’inde gelişti. Vasküler tutulumlu Behçet hastalarında vasküler tutulumun tespit edilmesini takiben hastaların %73,5’i sistemik immünsüpresif (İS) tedavi, %45,5’i antikoagülan tedavi almıştı. İS tedavi almayan grupta relaps riski anlamlı olarak yüksek bulundu. (p=0.001) Antikoagülan tedavi alan grupta relaps oranı daha fazla olmakla birlikte istatistiksel olarak anlamlı bir fark saptanmadı (p=0.61). Vasküler tutulum sıklıkla erkeklerde görülmektedir. Tedavide İS'ler ve antikoagülanlar kullanılmaktadır. İmmünsupresif tedavi kullanımı vasküler relaps riskini azaltabilir, ancak antikoagülan tedavinin ek faydası gösterilememiştir. Bu konuda daha fazla sayıda hasta ile yapılacak çok merkezli çalışmalara ihtiyaç vardır.

Anahtar Kelimeler

Antikoagülan tedavi, Behçet Hastalığı, immünsupresif tedavi, tromboz, vasküler tutulum.

Clinical Characteristics, Treatment Protocols and Relapse Rates of Patients with Vascular Behçet's Disease: A Single Center Experience

Öz

In this study, we aimed to evaluate the clinical and demographic data of the patients followed up with the diagnosis of Vascular Behçet's Disease (BD), and to examine the frequency of relapse and its relationship with the treatments used. The data of 512 patients diagnosed with BD were reviewed retrospectively, and 68 BD with vascular involvement were detected. Demographic characteristics, first vascular event, and recurrence, if any, and treatment protocols were recorded. The frequency of vascular involvement was 13.28%. 85% of the patients were man. Venous involvement was most common in the lower extremities. (77.9%) The first vascular relapse occurred in 29.4% of the patients, and the second vascular relapse occurred in 8.8%. After the first vascular event, 73.5% of the patients received systemic immunosuppressive therapy and 45.5% received anticoagulant therapy. The risk of relapse was found to be significantly higher in the group that did not receive immunosuppressive therapy. (p=0.001) Although the relapse rate was higher in the group receiving anticoagulant treatment, no statistically significant difference was found. (p=0.61) Vascular involvement often occurs in male patients. Immunosuppressive therapies and anticoagulants are used in the treatment. The use of immunosuppressive therapy can reduce the risk of vascular relapse. No additional benefit of anticoagulant therapy was observed. Multicenter studies with larger numbers of patients are needed for a better understanding in this issue.

Anahtar Kelimeler

Anticoagulant therapy, Behçet, immunosuppressive therapy, thrombosis, vascular involvement.

Kaynakça

• Behçet H. Uber rezidivierende, aphthose, durchein Virus verusachte Gaschwure am Mund, am Auge und an den Genitalien. Dermat Wochsch. 1937;105:1152–7.
• Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V. One year in review 2020: Behçet’s syndrome. Clin Exp Rheumatol. 2020; 38 Suppl 127(5):3–10.
• Hatemi G, Yazici Y, Yazici H. Behçet’s syndrome. Rheum Dis Clin North Am. 2013; 39(2):245-61.
• Calamia KT, Schirmer M, Melikoğlu M. Major vessel involvement in Behçet’s disease: an update. Curr Opin Rheumatol. 2011;23(1):24– 31.
• Kural-Seyahi E, Fresko I, Seyahi N et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Med (Baltimore). 2003; 82:60–76.
• Yazici H, Seyahi E, Hatemi G YY. Behcet syndrome: a contemporary view. Nat Rev Rheumatol. 2018; 14(2):107-119.
• Hatemi G, Christensen R, Bang D et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018;77(6):808–18.
• Alibaz-Oner F, Karadeniz A, Yılmaz S et al. Behcet Disease With Vascular Involvement Effects of Different Therapeutic Regimens on the Incidence of New Relapses. Med (Baltimore). 2015; 94(6):e494.
• Tascilar K, Melikoglu M, Ugurlu S, Sut N, Caglar E, Yazıcı H. Vascular involvement in Behcet’s syndrome: a retrospective analysis of associations and the time course. Rheumatol (Oxford). 2014; 53(11):2018-22.
• Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease. Lancet. 1990; 335(8697):1078-80.
• Chen Y, Cai JF, Lin CH GJ. Demography of vascular Behcet’s disease with different gender and age: an investigation with 166 Chinese patients. Orphanet J Rare Dis. 2019; 14(1):88.
• Sarica-Kucukoglu R, Akdag-Kose A, KayabalI M et al. Vascular involvement in Behçet’s disease: a retrospective analysis of 2319 cases. Int J Dermatol. 2006; 45(8):919-21.
• Saadoun D, Wechsler B, Desseaux K et al. Mortality in Behcet’s disease. Arthritis Rheum. 2010 Sep; 62(9):2806-12.
• Desbois AC, Wechsler B, Resche-Rigon M et al. Immunosuppressants reduce venous thrombosis relapse in Behçet’s disease. Arthritis Rheum 2012 Aug; 64 (8):2753-60.